Biohaven Says Two Phase 3 Clinical Trials For Migraine Met Effica
Biohaven Pharmaceutical announced positive top-line results from both of its two Phase 3 clinical trials of rimegepant, an oral CGRP receptor antagonist for the acute treatment of migraine. In each trial, rimegepant met the co-primary efficacy endpoints of superiority to placebo, at two hours post-dose, on pain freedom and freedom from the most bothersome symptom….